Bortezomib Clinical Trials
54 recruitingDrug
Phase 231Phase 317Phase 19Phase 41Not Applicable1
Showing 1–20 of 54 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
GlaxoSmithKline200 enrolled51 locationsNCT07227311
Recruiting
Phase 1Phase 2
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Acute Myeloid LeukemiaTP53
Masonic Cancer Center, University of Minnesota32 enrolled1 locationNCT07008638
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Amyloidosis
GlaxoSmithKline60 enrolled5 locationsNCT07224672
Recruiting
Phase 2
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
St. Jude Children's Research Hospital100 enrolled4 locationsNCT06390319
Recruiting
Phase 1Phase 2
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Multiple Myeloma
Karyopharm Therapeutics Inc300 enrolled25 locationsNCT02343042
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Pfizer1,116 enrolled127 locationsNCT05623020
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled271 locationsNCT06152575
Recruiting
Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Multiple Myeloma
Regeneron Pharmaceuticals317 enrolled42 locationsNCT05137054
Recruiting
Phase 3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
AbbVie380 enrolled166 locationsNCT06158841
Recruiting
Not Applicable
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
AL AmyloidosisAmyloidosis; Systemic
Jin Lu, MD41 enrolled7 locationsNCT06192979
Recruiting
Phase 2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center20 enrolled11 locationsNCT06083922
Recruiting
Phase 3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals915 enrolled20 locationsNCT07222761
Recruiting
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled138 locationsNCT07391657
Recruiting
Phase 3
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
Newly Diagnosed Multiple Myeloma
PETHEMA Foundation480 enrolled68 locationsNCT05558319
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaNon-Hodgkin LymphomaMultiple Myeloma+3 more
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Multiple Myeloma
Shanghai Zhongshan Hospital333 enrolled13 locationsNCT07663253
Recruiting
Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RISS Stage I Plasma Cell MyelomaRISS Stage II Plasma Cell MyelomaPlasma Cell Myeloma
ECOG-ACRIN Cancer Research Group1,450 enrolled649 locationsNCT04566328
Recruiting
Phase 1
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
LymphomaT-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center18 enrolled1 locationNCT07513129
Recruiting
Phase 3
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
SWOG Cancer Research Network510 enrolled397 locationsNCT05561387